Schott Pharma refines its long-term strategy, shares tracked in the SDAX healthcare space

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 15:08.

Schott Pharma (DE000A3ENQ51) positions itself as a specialist in pharmaceutical containment and drug delivery systems for injectable therapies. In the SDAX segment in Frankfurt, the stock offers a dedicated exposure to the growing biopharma and vaccines supply chain, which investors monitor alongside German peers like Sartorius.

How Schott Pharma earns money

Schott Pharma focuses on primary packaging solutions such as prefillable glass syringes, vials, cartridges and ampoules for injectable drugs, including biologics and vaccines, as described on its corporate site. The group also supplies drug delivery systems that integrate these containers into ready-to-use formats for pharmaceutical customers worldwide.

Strategic positioning in biopharma

Strategically, Schott Pharma targets long-term contracts with big pharma and biotech companies that rely on high-quality glass and polymer systems for complex biologics. The company emphasizes process capabilities around sterility, low particle counts and compatibility with sensitive formulations, which are critical for high-value biologic drugs and mRNA vaccines.

Key product lines in focus

One representative product line for Schott Pharma is its prefillable glass syringes used for biologic drugs and vaccines in hospital and outpatient settings. These syringes are designed for high dose accuracy and are compatible with modern auto-injectors, which large pharma companies use to improve patient comfort and adherence.

Listing and recent trading context

The Schott Pharma shares (DE000A3ENQ51) trade in Frankfurt on Xetra in euros, with the stock included in the SDAX segment for smaller German equities in the healthcare and chemicals-related space. The listing offers investors a specialized way to participate in long-term demand for injectable drug packaging and delivery systems.

This text is for information purposes only and does not constitute investment advice, recommendation or an offer to buy or sell securities. All information has been compiled with care; nevertheless, no guarantee is given for accuracy, completeness or timeliness. Investors should conduct their own research or consult a qualified financial adviser before making investment decisions.